XS-411

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameXS-411
Drug Alias NameiPSC-Derived Dopaminergic Neural Progenitor Cell therapy (XellSmart Bio-Pharmaceutical)XS411XS-411
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Dopaminergic neural orogenitor cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsParkinson DiseaseMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXellSmart Bio-Pharmaceutical (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXellSmart Bio-Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseMultiple System Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A